LDK1229
CAS No. 1800285-55-5
LDK1229 ( LDK 1229 )
Catalog No. M12734 CAS No. 1800285-55-5
LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLDK1229
-
NoteResearch use only, not for human use.
-
Brief DescriptionLDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.
-
DescriptionLDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM; exhibits 3-fold relative selectivity for the CB1 over CB2, exhibits efficacy comparable with SR141716A in antagonizing the basal G protein coupling activity of CB1; increases cell surface localization of CB1 and structurally distinct from the first-generation CB1 inverse agonists.
-
SynonymsLDK 1229
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCannabinoid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1800285-55-5
-
Formula Weight434.96
-
Molecular FormulaC24H29ClF2N2O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name(4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mahmoud MM, et al. Mol Pharmacol. 2015 Feb;87(2):197-206.
molnova catalog
related products
-
AM-1221
A potent and selective agonist for the cannabinoid receptor CB1 with Ki of 0.28 nM, 180-fold selectivity over CB2.
-
CP-724714(b)
CP-724714 is an effective and selective HER2/ErbB2 inhibitor (IC50: 10 nM), >640-fold selectivity against EGFR, Abl, InsR, PDGFR, IRG-1R, Src, VEGFR2, c-Met etc.
-
VCE-004.3
VCE-004.3 (VCE004.3) is a novel semi-synthetic cannabidiol derivative behaving as a dual PPARγ/CB2 agonist and CB1 receptor modulator.